June 12-17, 2016
Matrivax Research & Development Corporation is researching and developing a novel technology termed Protein Capsular Matrix Vaccine (PCMV) as an alternative to polysaccharide-protein conjugate vaccines. In a PCMV, polysaccharide antigens are entrapped in a cross-linked protein ‘carrier’ matrix. This process is simpler than conjugate vaccines and should yield polysaccharide vaccines that elicit TH-cell ‘memory’, are highly efficacious, and less expensive to manufacture.
Typhoid fever, caused by Salmonella enterica serovar Typhi, is a disease that afflicts ~16 million people worldwide, resulting in 600,000 deaths, annually. Although typhoid fever vaccines are commercially available, there are significant limitations. Ty21a is an oral vaccine that requires a multi-dose regimen; whereas Typherix® and TyphimVi® are parenteral and associated with local reactogenicity. The existing typhoid vaccines confer variable, ~70%, protective efficacy, do not protect young children (<2 years old), and are not used for routine immunization.
Please click Additional Files below to see the full abstract.
Kevin P. Killeen, "Development of Typhax, a Salmonella Typhi Vi polysaccharide protein capsular matrix vaccine" in "Vaccine Technology VI", Laura Palomares, UNAM, Mexico Manon Cox, Protein Sciences Corporation, USA Tarit Mukhopadhyay, University College London, UK Nathalie Garçon, BIOASTER Technology Research Institute, FR Eds, ECI Symposium Series, (2016). http://dc.engconfintl.org/vaccine_vi/5